14:09:53 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-16 X-dag ordinarie utdelning STENO 0.00 DKK
2024-05-15 Årsstämma 2024
2024-05-02 Kvartalsrapport 2024-Q1
2024-02-22 Bokslutskommuniké 2023
2024-02-05 Extra Bolagsstämma 2024
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-06-20 Kvartalsrapport 2023-Q1
2023-06-13 Extra Bolagsstämma 2023
2023-05-22 X-dag ordinarie utdelning STENO 0.00 DKK
2023-02-23 Bokslutskommuniké 2022
2022-11-18 Extra Bolagsstämma 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-20 X-dag ordinarie utdelning STENO 0.00 DKK
2022-05-19 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 X-dag ordinarie utdelning STENO 0.00 DKK
2021-05-20 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-15 X-dag ordinarie utdelning STENO 0.00 DKK
2020-05-14 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-06 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-05-07 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriLäkemedel & Handel
Stenocare är verksamt inom hälsovårdsindustrin. Bolaget är specialiserat inom utveckling av medicinsk cannabis. Stenocare är en av de första aktören att ha påbörjat försäljning av medicinska cannabisoljor i Danmark. Bolaget kommer framöver även vända sig till övriga europeiska marknader med sitt produktutbud. Stenocares huvudkontor ligger i Randers.
2024-05-31 10:04:41

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER:  STENO

STENOCARE A/S ("Stenocare") is providing an update on the progress of its robust product pipeline, spanning four stages from concept to commercialization. A significant milestone has recently been achieved with the innovative ASTRUM OIL product.

Since 2018, Stenocare has been the leading provider of medical cannabis oil products for the Danish Pilot Programme and has expanded into five other markets with approved products. Stenocare operates today in Denmark, Sweden, Norway, Germany, the United Kingdom, and Australia. The company consistently analyzes market opportunities and collects feedback from doctors to evaluate the product pipeline, fulfilling its mission to provide prescription-based medical cannabis products for patient treatment. See the table attached to this press release for more details.

ASTRUM Oil: Since 2019, the company has invested in qualifying and developing the new and innovative ASTRUM Oil product. Through a pharmacokinetic study with dogs, it has documented improved bioavailability in the blood, enhanced uniformity of uptake, and reduced time for maximum uptake. Bringing true innovation to the market is a multi-year investment, and the Australian market is the first to benefit from this new product in Q3 2024. Stenocare continues its efforts in developing ASTRUM Oil for new markets.

High CBD Oil: Stenocare has received feedback from doctors indicating a therapeutic need for a CBD Oil product with very high potency. Having successfully completed the concept stage and R&D stage for this product candidate, Stenocare has initiated the process of seeking approval for sales from the Medicines Agency.

In total, Stenocare has 13 medical cannabis oil products approved for sales across its six markets. Each product has been reviewed and approved by the individual medicines agencies for their local market.